Drug Database
Back to search

Italy· 036684088

APIDRA*5 cartucce SC 3 ml 300 U

A insulin glulisine product containing insulina glulisina, registered in Italy by SANOFI AVENTIS DEUTSCHL.GMBH, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC A10AB06

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedAPIDRA*5 cartucce SC 3 ml 300 UATCA10AB06REGISTER NO.036684088PACKS LISTED1CHECKEDJune 4, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about insulina glulisinaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Insulin glulisine is registered in 14 of 19 countries.

Countries holding a registration under ATC A10AB06 (insulin glulisine), each read from that country’s own register.

  • This record: Italy
  • 9 of them publish a price we can compare per daily dose
Search insulin glulisine products by name

Insulin glulisine · ATC A10AB06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Active substance
Insulina glulisina
Manufacturer
SANOFI AVENTIS DEUTSCHL.GMBH
Country
Italy (IT)
ATC code
A10AB06
ATC class
Insulin glulisine
Defined daily dose
40 E, P
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    036684088
    APIDRA*5 cartucce SC 3 ml 300 U
    EUR 46.92

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

434 interactions on record for insulin glulisine.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check insulin glulisine against other medicinesHow interaction checks work

Insulin glulisine · interactions on record

434 records

  • 15 severe
  • 368 moderate
  • 50 minor

Most severe, free to view

  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • PrednisoloneA07EA01moderate

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Insulin glulisine in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All insulin glulisine products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Apidra, Apidra Solostar
  • Liechtenstein · Apidra, Apidra Solostar
  • Norway · Apidra, Apidra Solostar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/37bce93e-5c18-41e4-a02a-4d260a472db5
GET /v1/drugs/37bce93e-5c18-41e4-a02a-4d260a472db5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 46.92,
  "source": "aifa",
  "currency": "EUR",
  "strength": "INSULINA GLULISINA 300U 3ML 5 UNITA' USO PARENTERALE",
  "substance": "Insulina glulisina",
  "equivalence_group": "N5B",
  "transparency_flag": null
}
API referenceMCP serverPlans

See everything about insulin glulisine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console